Table 1.

Timeline showing variations of creatinine, urea, urinary protein: creatinine ratio (UPC), urine specific gravity (USG), total proteins (TP), albumin (Alb) and the prescribed medical treatment

Time points/medical treatment	Creatinine mg/dl (RI 0.8–1.6)	Urea mg/dl (RI 30–60)	UPC (<0.2)	USG	TP g/dl (RI 6–8.2)	Alb g/dl (RI 2.5–3.9)
Diagnosis – Started on allopurinol 10 mg/kg PO q12h – Allopurinol stopped 5 days later owing to a suspicion of CADR	0.9	62.5	0.6	1.035	9	1.5
Day 0 – Started on meglumine antimoniate 50 mg/kg SC q24h	1.2	75.9	0.6	1.035	9.6	2.5
Day 10 – Meglumine antimoniate was continued	1.2	20	*	1.025	9.6	2.7
Day 25 – Meglumine antimoniate was discontinued – Hospitalisation for fluid therapy, supportive and ocular treatment	6.5	119	*	1.030	9.1	2.8
Day 34 – Hospital discharge	0.9	31.4	*	*	*	*
Day 44 – Started on N-AHCC ½ tablet PO q24h + benazepril 0.5 mg/kg PO q24h	1.8	117.8	0.4	1.030	7.58	3.59
Day 123 – N-AHCC + benazepril were continued	1.89	93.4	0.3	1.030	8.8	3.0
Day 162 – Started on miltefosine 2 mg/kg PO q24h for 28 days; N-AHCC + benazepril were continued	1.9	83	0.3	1.028	8.8	2.9
Day 180 – Hospitalisation for fluid therapy and supportive treatment. Miltefosine and N-AHCC were continued; benazepril was discontinued	3.84	141.9	*	*	9.35	2.96
Day 188 – Hospital discharge	1.96	103.8	<0.2	*	*	*
Day 204 – N-AHCC, renal diet, SC regular fluid therapy, intermittent administration of maropitant	2.33	120.6	<0.2	1.028	*	*
Day 213 – Same medical therapy and diet	3.28	198.9	*	1.025	8.19	3.1
Day 268 – Same medical therapy and diet	3.67	138.1	*	1.028	8.57	3.16
Day 315 – Same medical therapy and diet	3.31	115	<0.2	1.025	8.2	3.14

RI = reference interval; CADR = cutaneous adverse drug reaction; N-AHCC = nucleotides and active hexose correlated compounds

^*refers to missing data at each time-point